Trial Profile
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bemarituzumab (Primary) ; Depatuxizumab (Primary) ; Nivolumab (Primary) ; Ramucirumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PANGEA
- 15 Mar 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (Data cut off 2/1/20) assessing temporal molecular heterogeneity rates at progressive disease points (PD1 & PD2), ORR/PFS/DCR in each of 3 tx lines, time to strategy failure (TTF), & updated OS/safety, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology